sglt2 with glp 1 Renal outcomes of inhibitors and GLP1 agonists in clinical practice Prescribe SGLT2 inhibitors, GLP-1 receptor

Pushes Into Phase 3 With Strong Momentum Viking Therapeutics advanced its dual GLP-1/GIP agonist VK2735 into Phase 3 after achieving 14.7% weight loss without plateauing in Phase 2, positioning the program as a serious challenger in a rapidly expanding $150B obesity market

Higher concentrations trade off tolerability and formulation stability

According to the agency, injectable glutathione for skin lightening carries risks of toxic effects on the thyroid, liver, kidneys, and nervous system, Steven Johnson Syndrome and Toxic Epidermal Necrolysis, along with long-term skin cancer risk

doi:10.1038/nature04056

Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis